Teva Stock Has More Than Doubled in a Year. Where Will It Be in 3 Years?

Teva Pharmaceutical has surged 108% over the past year due to its successful pivot from generic drugs to branded drugs. The company's flagship branded drugs (Ajovy, Austedo, Uzedy) are showing strong growth with year-over-year revenue increases of 40-56%. Analysts project moderate continued gains with potential stock price reaching low-$50s in three years, though a 38% price reduction for Austedo effective January 2027 poses a potential headwind.